Drosera
DROSERA ROTUNDIFOLIA
ORAL
HUMAN OTC DRUG
Drosera is an FDA drug label for the active ingredient DROSERA ROTUNDIFOLIA manufactured by Boiron administered by ORAL. This page reproduces the FDA-approved indications and usage, dosage, contraindications, warnings, and adverse reactions exactly as published in the drug label. Data source: openFDA (U.S. FDA), label effective 20231113.
- Generic name
- DROSERA ROTUNDIFOLIA
- Manufacturer
- Boiron
- Product type
- HUMAN OTC DRUG
- Route
- ORAL
- Dosage form
- N/A
- NDC
- 0220-1784
- Application
- N/A
- Label effective
- 20231113
Active ingredients
Drosera 5C (**contains 0.443 mg of the active ingredient per pellet)
Indications & Usage
Spasmodic Dry Cough Worsened At Night And By Heat*
Dosage & Administration
Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.
Contraindications
Not available.
Warnings
Not available.
Adverse Reactions
Not available.